Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Theranexus and Its Partners Receive Support from the FUI (French Inter-ministry Fund) for Their Project, Cx-COG

Posted on: 20 Sep 16

Theranexus, a clinical-stage biopharmaceutical company, has announced today that it has received funding from the FUI (French Inter-ministry Fund) for its project CX-COG (FUI AAP22) which has been approved by the competitiveness clusters Lyonbiopôle and Atlanpôle Biothérapies. This project, which will be carried out in collaboration with the team of Prof. Régis Bordet (Lille University, Lille University Hospital, Inserm) and the company Synerlab, concerns the pharmaceutical formulation development and clinical validation of the efficacy of THN201 in the treatment of neurocognitive impairment particularly associated with Alzheimer’s disease.

The goal of the project launched by Theranexus is to demonstrate the clinical performance of an innovative proprietary combination of donepezil, a reference treatment for neurocognitive impairment, and an existing medication that improves the efficacy of donepezil fivefold.

The outcome sought from this development is to rapidly strengthen the therapeutic arsenal by inducing a 12 to 18 month delay in cognitive decline and placement in a care facility among patients affected by neurocognitive impairment. Currently available therapeutic options against neurocognitive impairment, that is mostly associated with Alzheimer’s disease, are only able to modestly slow the evolution of impairment towards more severe forms.

Project CX-COG, which coordinator is Theranexus, is being carried out in partnership with the company Synerlab Développement, which is specialised in the development of original pharmaceutical formulations, and with the team of Prof. Régis Bordet (Joint research unit [UMR-S] 1171 & Clinical Investigation Centre [CIC] of Lille), who is an internationally recognised expert in the clinical evaluation of neurocognitive impairment and new therapies.

The partners of the CxCOG consortium now plan to initiate at the earliest possible time the foreseen characterisation work in in vivo models and in healthy subjects, of the tolerance and pharmacokinetic parameters of THN201. Work towards developing an innovative formulation for the product will also be carried out alongside these activities. Once accomplished, these tasks should make it possible to launch a clinical proof-of-concept study within 15 months. The study itself should last 15 months as well.

Details on:

View source version on

Business Wire

Last updated on: 20/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.